Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis

摘要

Methods of treating, inhibiting, or ameliorating polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA) in an adult or juvenile human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein PMR and/or GCA are inhibited, or ameliorated. The IL-1 antagonist is an IL-1 antagonist (“trap”), preferably comprising a sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical having at least 95% identity to the sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and capable of binding and inhibiting IL-1.